You are a medical doctor specialized in cancer diagnosis. 
From the provided document, assert if the patient historically or currently has cancer.
For each condition, only pick from "YES", "NO", or "MAYBE". And you must following format without anything further. The results have to be directly parseable with python json.loads(). 
Sample output: {"cancer": 'MAYBE'}.
Never output anything beyond the format.
Provided document: 
Discharge Summary:

Patient: 38-year-old male, with vitiligo and hypothyroidism
Diagnosis: Primary epithelioid angiomyolipoma (EAML) with metastatic disease
Hospital Course:

The patient initially presented in 2011 with gross hematuria, and was diagnosed with a 6-cm renal mass concerning for malignancy. He underwent right radical nephrectomy, and the pathology revealed a primary EAML with limited renal parenchyma involvement. The patient had an uneventful course for 3 years until monitoring identified an asymptomatic 13-cm renal fossa mass in 2014. Repeat surgical resection confirmed recurrent EAML, followed by a third surgical resection with indeterminate margins. In 2014, metastatic EAML was discovered after new retroperitoneal and pelvic implants were detected via surveillance imaging. 

The patient was initiated on everolimus in January 2015 based on a TSC2 deletion revealed during the FoundationOne® targeted next-generation sequencing. A follow-up imaging at 3 months showed a marked reduction in size of the majority of the soft tissue masses. Nonetheless, in September 2015, the patient reported unintended weight loss. Imaging identified slight enlargement of the dominant right renal fossa mass, with progressive anemia indicating disease progression. Everolimus was discontinued and a treatment-directed biopsy was conducted for consideration of a clinical trial.

Paired tumor-germline next-generation sequencing via MSK-IMPACT was performed, but there were no new somatic variants identified to explain the tumors’ acquired resistance. Thus, the patient was offered a clinical trial of off-label nivolumab via the Bristol-Myers Squibb Expanded Access program, and he received two cycles of treatment efficiently. Following nivolumab therapy, imaging after 5 cycles of nivolumab revealed responding disease, and the patient continued the treatment for a total of 2 years. Despite immune-related exacerbation of pre-existing hypothyroidism and cutaneous eruption primarily in areas of pre-existing vitiligo, no dose-limiting toxicities were reported by the patient. 

Nivolumab was discontinued in November 2017 after the patient had already completed 2 years of therapy, as it was deemed that the toxicities would become more severe. The most recent imaging demonstrated continued response and interval calcification of the patient's intra-abdominal tumors. Playback tissue derived from the surgical resection showed high PD-L1 expression and preserved expression of key DNA mismatch repair (MMR) proteins MSH2, MSH6, PMS2, and MLH1, confirming MMR proficiency. 

Disposition: The patient was discharged from hospital care upon the completion of nivolumab therapy. Further follow-up was recommended to monitor any future disease progression.
